Journal Article

Susceptibility of European β-lactamase-positive and -negative <i>Haemophilus influenzae</i> isolates from the periods 1997/1998 and 2002/2003

A. C. Fluit, A. Florijn, J. Verhoef and D. Milatovic

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 1, pages 133-138
Published in print July 2005 | ISSN: 0305-7453
Published online May 2005 | e-ISSN: 1460-2091 | DOI:
Susceptibility of European β-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003

Show Summary Details


Aims: To test prospectively the activity of cefixime and comparators against Haemophilus influenzae from Europe and to compare the susceptibilities of isolates from 1997/1998 with isolates from 2002/2003 paying special attention to the epidemiology of amoxicillin resistance.

Methods: MICs of antibiotics were determined using broth microdilution. For β-lactamase-negative isolates with reduced susceptibility to amoxicillin, the nucleotide sequence of the penicillin-binding domain of PBP3 was determined.

Results: The prevalence of β-lactamase-positive isolates in certain countries has reached 38%. During the period 1997/1998, 8.8% of the isolates were β-lactamase-negative and non-susceptible to amoxicillin (BLNAR). During the period 2002/2003, 9.6% of the isolates were BLNAR. The emergence of the BLNAR phenotype of H. influenzae was demonstrated in all countries with a prevalence ranging from 2% to 20%. The penicillin-binding domain of PBP3 from 30 sequenced isolates showed known amino acid substitutions, although no amino acid changes were observed in two BLNAR isolates. Clonal spread of BLNAR strains was limited or absent in our study. Both β-lactamase-producing and BLNAR strains of H. influenzae were fully susceptible to cefixime. However, neither β-lactamase-producing nor BLNAR isolates were fully susceptible to the other cephalosporins tested. All isolates were also fully susceptible to levofloxacin, moxifloxacin, azithromycin and telithromycin.

Conclusions: The prevalence of the BLNAR phenotype in Europe is increasing, but no new amino acid substitutions were detected in the penicillin-binding domain of PBP3. Cefixime remains a useful treatment option for respiratory tract infections, including in areas with increasing resistance problems.

Keywords: PBP3; surveillance; cefixime

Journal Article.  3045 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.